Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Arlington Capital Partners Announces the Acquisition of Micron Technologies

Published: Thursday, March 21, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
Arlington Capital Partners, a Washington announced the acquisition of Micron Technologies, Inc., in partnership with the company’s management team.

Headquartered in Malvern, PA, Micron is a leading global provider of particle size engineering and related analytical services to the pharmaceutical industry.

Micron focuses on solving the pharmaceutical industry’s most difficult bio-availability and drug delivery challenges through multiple particle size reduction technologies. The Company is the leading independent provider of micronization services for solubility enhancement of active pharmaceutical ingredients (“APIs”). Micron maintains state of the art facilities offering industry leading capabilities including distinctive containment technology for processing highly potent compounds. Micron’s personnel have unique expertise in jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring.

“Micron’s ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the Company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs,” said Matt Altman, a Partner at Arlington Capital Partners. “We are enthusiastic about building upon the Company’s leadership position and eager to continue to support the Company as it enhances and expands its global particle size engineering and analytical service offerings.”

Joseph Drost, CEO of Micron, commented, “We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings.

Arlington’s ability to provide significant strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”

David Wodlinger, a Principal at Arlington Capital said, “Micron is an ideal platform investment in a compelling growth industry and we look forward to working closely with the company’s management team to expand the business aggressively, both organically and through acquisition.”

Greenberg Traurig served as counsel to Arlington Capital Partners for the transaction. Fairmount Partners advised Micron on the transaction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!